^(131)I-chTNT联合射频消融在中期肝癌的观察与护理对策  

Nursing care for patients with mid- stage hepatocellular carcinoma treated with ^(131)I- chTNT combined with radiofrequency ablation

作　　者：王淑芳[1] 郑群丽[1] 涂建飞[1] 

机构地区：[1]浙江省丽水市中心医院,323000

出　　处：《介入放射学杂志》2014年第8期732-734,共3页Journal of Interventional Radiology

基　　金：浙江省科技厅社会公益项目(2010C33113)

摘　　要：目的研究131I-chTNT联合射频消融(RFA)治疗中期肝癌的护理方法。方法回顾性分析2009年8月—2011年9月间12例原发性肝癌(中期)患者的临床资料,所有患者均采用RFA联合131IchTNT治疗,术前给予预防性抗过敏和保护甲状腺,术后加强放射防护及并发症的观察和护理工作。结果本组患者经治疗和护理后,肿块均有缩小,随访5~48个月,中位随访时间31个月。中位总生存时间43个月,均未发生严重并发症,未出现骨髓抑制及甲状腺功能损伤病例。结论 131I-chTNT联合RFA治疗中期肝癌效果良好,治疗中严密观察并发症,精心的护理能提高患者的生活质量,延长生存期。Objective To summarize the nursing points for patients with mid-stage hepatocellular carcinoma who are receiving radiofrequency ablation （RFA） combined with ^131I-chTNT treatment. Methods The clinical data of 12 patients with mid-stage hepatocellular carcinoma, who were encountered at authors’ hospital during the period from Aug. 2009 to Sep. 2011, were retrospectively analyzed. RFA combined with ^131I-chTNT was carried out in all patients. Preoperative prophylactic anti-allergy medication and protection measure for the thyroid were employed. After the operation strengthened radiation protection and close observation for complications were conducted. The results were analyzed. Results After active treatment and proper nursing, the tumor shrank in all patients. All the patients were followed up for 5 - 48 months with a median follow- up time of 31 months. The median overall survival time was 43 months. No serious complications such as bone marrow suppression or thyroid dysfunction occurred. Conclusion For the treatment of mid-stage hepatocellular carcinoma, ^131I-chTNT combined with RFA has satisfactory therapeutic effect. Close observation for the occurrence of complications and careful nursing can improve the quality of life and prolong the survival time.

关 键 词：肝癌 ^131I-chTNT单抗 射频消融术 护理 

分 类 号：R473.73[医药卫生—护理学]